Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Single Group, Open-label Multicenter Phase 2 Study With Single-dose Administration of the Optical Imaging Agent FG001 in Subjects With Newly Diagnosed High Grade Glioma Scheduled for Neurosurgical Tumor Resection Under NIR Fluorescence Guidance

NCT07609472 is registered in ClinicalTrials.gov with FluoGuide A/S as lead sponsor.

NCT NCT07609472
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07609472 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Single Group, Open-label Multicenter Phase 2 Study With Single-dose Administration of the Optical Imaging Agent FG001 in Subjects With Newly Diagnosed High Grade Glioma Scheduled for Neurosurgical Tumor Resection Under NIR Fluorescence Guidance
Lead sponsor
FluoGuide A/S
Phase
Phase 2
Overall status
Not yet recruiting
Start date
June 30, 2026
Completion date
July 31, 2028
Enrollment
76 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

high-grade glioma (who iii-iv)